PMID- 17459426
OWN - NLM
STAT- MEDLINE
DCOM- 20071025
LR  - 20220309
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 52
IP  - 8
DP  - 2007 Jun
TI  - Voltammetric characterization of the effect of monoamine uptake inhibitors and 
      releasers on dopamine and serotonin uptake in mouse caudate-putamen and 
      substantia nigra slices.
PG  - 1596-605
AB  - Fast scan cyclic voltammetry is an electrochemical technique used to measure 
      dynamics of transporter-mediated monoamine uptake in real time and provides a 
      tool to evaluate the detailed effects of monoamine uptake inhibitors and 
      releasers on dopamine and serotonin transporter function. We measured the effects 
      of cocaine, methylphenidate, 2beta-propanoyl-3beta-(4tolyl) tropane (PTT), 
      fluoxetine, amphetamine, methamphetamine, 3,4-methylenedioxymethamphetamine 
      (MDMA), phentermine and fenfluramine on dopamine and serotonin uptake following 
      electrically stimulated release in mouse caudate-putamen and substantia nigra 
      pars reticulata slices. We determined rank orders of uptake inhibition effects 
      based on two variables; increases in apparent K(m) for dopamine and serotonin 
      uptake and inhibition constant (K(i)) values. For example, the rank order of 
      uptake inhibition based on apparent K(m) values at the dopamine transporter was 
      amphetamine>or=PTT>or=methylphenidate>>methamphetamine=phentermine=MDMA>cocaine>>fluoxetine=fenfluramine, 
      and at the serotonin transporter was fluoxetine=methamphetamine=fenfluramine=MDMA 
      > amphetamine=cocaine=PTT>or=methylphenidate>phentermine. Additionally, changes 
      in electrically stimulated release were documented. This is the first study using 
      voltammetry to measure the effects of a wide range of monoamine uptake inhibitors 
      and releasers on dopamine and serotonin uptake in mouse brain slices. These 
      studies also highlight methodological considerations for comparison of effects 
      between heterogeneous brain regions.
FAU - John, Carrie E
AU  - John CE
AD  - Wake Forest University School of Medicine, Department of Physiology and 
      Pharmacology, Medical Center Boulevard, Winston-Salem, NC 27157, USA.
FAU - Jones, Sara R
AU  - Jones SR
LA  - eng
GR  - R21 DA018815/DA/NIDA NIH HHS/United States
GR  - U01 AA014091/AA/NIAAA NIH HHS/United States
GR  - DA016498/DA/NIDA NIH HHS/United States
GR  - R21 AA013900-03/AA/NIAAA NIH HHS/United States
GR  - AA013900/AA/NIAAA NIH HHS/United States
GR  - R21 DA018815-02/DA/NIDA NIH HHS/United States
GR  - R21 AA013900/AA/NIAAA NIH HHS/United States
GR  - R01 DA021325/DA/NIDA NIH HHS/United States
GR  - AA014091/AA/NIAAA NIH HHS/United States
GR  - F31 DA016498/DA/NIDA NIH HHS/United States
GR  - DA018815/DA/NIDA NIH HHS/United States
GR  - F31 DA016498-03/DA/NIDA NIH HHS/United States
GR  - U01 AA014091-05/AA/NIAAA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20070316
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Neurotransmitter Uptake Inhibitors)
RN  - 333DO1RDJY (Serotonin)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Animals
MH  - Caudate Nucleus/*drug effects
MH  - Dopamine/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Electrochemistry/methods
MH  - Female
MH  - In Vitro Techniques
MH  - Inhibitory Concentration 50
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Models, Statistical
MH  - Neurotransmitter Uptake Inhibitors/*pharmacology
MH  - Putamen/*drug effects
MH  - Serotonin/*metabolism
MH  - Substantia Nigra/*drug effects
PMC - PMC2041899
MID - NIHMS26152
EDAT- 2007/04/27 09:00
MHDA- 2007/10/27 09:00
PMCR- 2008/06/01
CRDT- 2007/04/27 09:00
PHST- 2006/08/03 00:00 [received]
PHST- 2007/02/28 00:00 [revised]
PHST- 2007/03/07 00:00 [accepted]
PHST- 2007/04/27 09:00 [pubmed]
PHST- 2007/10/27 09:00 [medline]
PHST- 2007/04/27 09:00 [entrez]
PHST- 2008/06/01 00:00 [pmc-release]
AID - S0028-3908(07)00063-9 [pii]
AID - 10.1016/j.neuropharm.2007.03.004 [doi]
PST - ppublish
SO  - Neuropharmacology. 2007 Jun;52(8):1596-605. doi: 
      10.1016/j.neuropharm.2007.03.004. Epub 2007 Mar 16.